{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T13:59:57Z","timestamp":1792936797601,"version":"4.5.0"},"reference-count":25,"publisher":"Japanese Society of Internal Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2169\/internalmedicine.56.7862","type":"journal-article","created":{"date-parts":[[2017,4,30]],"date-time":"2017-04-30T22:11:27Z","timestamp":1493590287000},"page":"1085-1088","source":"Crossref","is-referenced-by-count":5,"title":["Long-term Eculizumab Treatment Contributes to Recovery from End-stage Renal Disease Caused by Atypical Hemolytic Uremic Syndrome"],"prefix":"10.2169","volume":"56","author":[{"given":"Yuji","family":"Yamada","sequence":"first","affiliation":[{"name":"Department of Medicine, Kawasaki Municipal Kawasaki Hospital, Japan"},{"name":"Department of Medicine, Mount Sinai Beth Israel, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kawasaki Municipal Kawasaki Hospital, Japan"},{"name":"Division of Hematology, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Okano","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kawasaki Municipal Kawasaki Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Miyakawa","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kawasaki Municipal Kawasaki Hospital, Japan"},{"name":"Department of General Internal Medicine, Saitama Medical University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 8: 622-633, 2012.","DOI":"10.1038\/nrneph.2012.195"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kaplan BS, Meyers KE, Schulman SL. The pathogenesis and treatment of hemolytic uremic syndrome. J Am Soc Nephrol 9: 1126-1133, 1998.","DOI":"10.1681\/ASN.V961126"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368: 2169-2181, 2013.","DOI":"10.1056\/NEJMoa1208981"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Yoshida Y, Miyata T, Matsumoto M, et al. A novel quantitative hemolytic assay coupled with restriction fragment length polymorphisms analysis enabled early diagnosis of atypical hemolytic uremic syndrome and identified unique predisposing mutations in Japan. PLoS One 10: e0124655, 2015.","DOI":"10.1371\/journal.pone.0124655"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 18: 2392-2400, 2007.","DOI":"10.1681\/ASN.2006080811"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 371: 654-666, 2014.","DOI":"10.1056\/NEJMra1312353"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Tsai HM. Untying the knot of thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome. Am J Med 126: 200-209, 2013.","DOI":"10.1016\/j.amjmed.2012.09.006"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 361: 1676-1687, 2009.","DOI":"10.1056\/NEJMra0902814"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kavanagh D, Goodship THJ. Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations. Hematology Am Soc Hematol Educ Program 2011: 15-20, 2011.","DOI":"10.1182\/asheducation-2011.1.15"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Taylor CM, Machin S, Wigmore SJ, Goodship THJ. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol 148: 37-47, 2010.","DOI":"10.1111\/j.1365-2141.2009.07916.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Saland J. Liver-kidney transplantation to cure atypical HUS: still an option post-eculizumab? Pediatr Nephrol 29: 329-332, 2014.","DOI":"10.1007\/s00467-013-2722-2"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8: 554-562, 2013.","DOI":"10.2215\/CJN.04760512"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kato H, Nangaku M, Hataya H, et al. Clinical guides for atypical hemolytic uremic syndrome in Japan. Pediatr Int 58: 549-555, 2016.","DOI":"10.1111\/ped.13044"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108: 1267-1279, 2006.","DOI":"10.1182\/blood-2005-10-007252"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Richards A, Kemp EJ, Liszewski MK, et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 100: 12966-12971, 2003.","DOI":"10.1073\/pnas.2135497100"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Delvaeye M, Noris M, De Vriese A, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 361: 345-357, 2009.","DOI":"10.1056\/NEJMoa0810739"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Fan X, Yoshida Y, Honda S, et al. Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome. Mol Immunol 54: 238-246, 2013.","DOI":"10.1016\/j.molimm.2012.12.006"},{"key":"18","first-page":"27","volume":"33","author":"JM Campistol","year":"2013","unstructured":"18. Campistol JM, Arias M, Ariceta G, et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 33: 27-45, 2013.","journal-title":"Nefrologia","ISSN":"https:\/\/id.crossref.org\/issn\/0211-6995","issn-type":"print"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Cataland SR, Holers VM, Geyer S, Yang S, Wu HM. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood 123: 3733-3738, 2014.","DOI":"10.1182\/blood-2013-12-547067"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Noris M, Galbusera M, Gastoldi S, et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 124: 1715-1726, 2014.","DOI":"10.1182\/blood-2014-02-558296"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Gavriilaki E, Yuan X, Ye Z, et al. Modified Ham test for atypical hemolytic uremic syndrome. Blood 125: 3637-3646, 2015.","DOI":"10.1182\/blood-2015-02-629683"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Magro CM, Momtahen S, Mulvey JJ, Yassin AH, Kaplan RB, Laurence JC. Role of the skin biopsy in the diagnosis of atypical hemolytic uremic syndrome. Am J Dermatopathol 37: 349-356-quiz357-359, 2015.","DOI":"10.1097\/DAD.0000000000000234"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Greenbaum LA, Fila M, Ardissino G, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 89: 701-711, 2016.","DOI":"10.1016\/j.kint.2015.11.026"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 373: 759-767, 2009.","DOI":"10.1016\/S0140-6736(09)60001-5"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Ardissino G, Testa S, Possenti I, et al. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis 64: 633-637, 2014.","DOI":"10.1053\/j.ajkd.2014.01.434"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/9\/56_56.7862\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T10:33:38Z","timestamp":1692786818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/9\/56_56.7862\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.56.7862","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}